Key result
POLARx cryoballoon achieves similar acute PVI efficacy compared to AFA-Pro.
Why the study?
A novel cryoballoon system (POLARx) with a more compliant design became available, prompting comparison with the Arctic Front Advance Pro (AFA-Pro) system for procedural efficacy, biophysical parameters, and safety.
Does the POLARx cryoballoon provide similar procedural efficacy and safety compared to the AFA-Pro cryoballoon in patients undergoing pulmonary vein isolation for atrial fibrillation?
Meta-Analysis (n=310)
Yes
Does the POLARx cryoballoon provide similar procedural efficacy and safety compared to the AFA-Pro cryoballoon in patients undergoing pulmonary vein isolation for atrial fibrillation?
The novel POLARx cryoballoon provides comparable acute procedural success and safety profile to the widely used AFA-Pro system for pulmonary vein isolation in atrial fibrillation.
Answers are grounded in this paper and cite their sources.
Similar acute PVI efficacy and safety support either cryoballoon for AF ablation; extends direct comparisons of POLARx versus AFA-Pro.
INTRODUCTION: In May 2020, a novel cryoballoon system (POLARx; Boston Scientific) became available for catheter ablation of atrial fibrillation (AF). The design of the cryoballoon is comparable to the Arctic Front Advance Pro (AFA-Pro; Medtronic), but it is more compliant during freezing. We compared the procedural efficacy, biophysical parameters, and risk of phrenic nerve palsy (PNP) between the two cryoballoons. METHODS: Embase, MEDLINE, Web of Science, Cochrane, and Google Scholar databases were searched until June 1, 2021 for relevant studies comparing POLARx versus AFA-Pro in patients undergoing pulmonary vein isolation (PVI) for AF. RESULTS: A total of four studies, involving 310 patients were included. There was no difference between the two groups for outcomes regarding procedural efficacy: acute PVI (odds ratio [OR]: 0.43; 95% confidence interval [CI]: 0.06 to 3.03; p = .40), procedure time (mean difference [MD]: 8.15 min; 95% CI: -8.09 to 24.39; p = .33), fluoroscopy time (MD: 1.32 min; 95% CI: -1.61 to 4.25; p = .38) and ablation time (MD: 1.00 min; 95% CI: -0.20 to 2.20; p = .10). The balloon nadir temperature was lower for all individual pulmonary veins (PV) in POLARx compared with AFA-Pro (MD: -9.74°C, -9.98°C, -6.72°C, -7.76°C, for left superior PV, left inferior PV, right superior PV, and right inferior PV, respectively; all p < .001). The incidence of PNP was similar between groups (OR: 0.79; 95% CI: 0.22 to 2.85; p = .72). CONCLUSION: In AF patients undergoing PVI, POLARx and AFA-Pro had a similar procedural efficacy. Balloon nadir temperatures were lower with POLARx, however, the incidence of PNP was similar.
No takes yet. Share an insight, caveat, or question.
Assaf et al. (2021) conducted a meta-analysis in Atrial Fibrillation (n=310). POLARx cryoballoon vs. Arctic Front Advance Pro (AFA-Pro) cryoballoon was evaluated on Acute pulmonary vein isolation (PVI) (OR 0.43, 95% CI 0.06 to 3.03, p=0.40). The POLARx cryoballoon demonstrated similar acute procedural efficacy for pulmonary vein isolation compared to the AFA-Pro cryoballoon.
Synapse has enriched 10 related papers. Consider them for comparative context: